Episode

Author Interview: Professor Matthew Brown, 2026

Podcast
The IMID Forum
Published
Feb 3, 2026
Duration seconds
1109
Processing state
not_requested
Canonical source
https://soundcloud.com/imidforum/author-interview-professor-matthew-brown-2026
Audio
https://feeds.soundcloud.com/stream/2259424706-imidforum-author-interview-professor-matthew-brown-2026.mp3
JSON
/v1/public/podcasts/the-imid-forum-981476/episodes/author-interview-professor-matthew-brown-2026
Markdown
/podcast/the-imid-forum-981476/author-interview-professor-matthew-brown-2026.md

Actions

  • POST https://stenobird.com/v1/public/podcasts/the-imid-forum-981476/episodes/author-interview-professor-matthew-brown-2026/transcription-requests
    Idempotently request low-priority transcript generation for this episode.
  • GET https://stenobird.com/podcast/the-imid-forum-981476/author-interview-professor-matthew-brown-2026.md
    Read the agent-friendly Markdown representation of this episode resource.

Summary

Join Professor Peter Nash from the Griffith University in Brisbane, and Professor Matthew Brown, the Chief Scientific Officer at Genomics England, as they discuss his recent paper ‘Low uveitis rates in patients with axial spondyloarthritis treated with bimekizumab: Pooled results from Phase 2b/3 trials’.